Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Stock Has Consensus Price Target of $38.67

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) have received a consensus rating of “Hold” from the five research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $38.67.

Several research firms have recently commented on PHAR. Canaccord Genuity Group set a $38.00 target price on shares of Pharming Group in a report on Wednesday, September 23rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Pharming Group in a research note on Friday, August 7th. Zacks Research downgraded shares of Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. HC Wainwright reiterated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research note on Tuesday, September 22nd. Finally, Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP purchased a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group makes up 6.0% of MAC Alpha Capital Management LP’s holdings, making the stock its 2nd biggest holding. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group as of its most recent SEC filing. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Pharming Group Stock Performance

NASDAQ PHAR opened at $9.53 on Friday. The firm has a market cap of $674.53 million, a price-to-earnings ratio of 79.42 and a beta of -0.05. The company has a quick ratio of 2.31, a current ratio of 3.01 and a debt-to-equity ratio of 0.34. The business has a 50-day moving average price of $10.96 and a 200-day moving average price of $13.10. Pharming Group has a twelve month low of $9.44 and a twelve month high of $21.34.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. As a group, equities research analysts predict that Pharming Group will post 0.22 EPS for the current fiscal year.

About Pharming Group

Pharming Group N.V. is a global biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and conditions with significant unmet medical needs, using biotechnology and protein-replacement approaches.

Pharming’s commercial products include Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral therapy for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency disorder.